Pancreas Cancer Survival in the Gemcitabine Era
Author Information
Author(s): Wachtel Mitchell S., Xu K. Tom, Zhang Yan, Chiriva-Internati Maurizio, Frezza Eldo E.
Primary Institution: Texas Tech University Health Sciences Center
Hypothesis
Analyzing survival differences between the gemcitabine and the pre-gemcitabine era might shed light on whether gemcitabine has improved survival for pancreas cancer patients.
Conclusion
The study provides evidence that gemcitabine has led to increased survival for patients with metastatic pancreas cancer who underwent surgery.
Supporting Evidence
- Patients with metastatic cancer who underwent surgery showed a 60% increase in survival.
- Patients without metastases and no surgery showed no improvement in survival during the gemcitabine era.
- Radiotherapy was associated with a survival time increase of over 50%.
Takeaway
This study looked at how long people with pancreas cancer lived before and after a new medicine called gemcitabine was used. It found that people who got surgery and had the medicine lived longer.
Methodology
The study analyzed SEER data comparing survival rates of pancreas cancer patients during the gemcitabine era (1998-2004) and the pre-gemcitabine era (1988-1997), adjusting for various factors.
Potential Biases
Selection bias may exist as patients with known metastatic disease are less likely to undergo surgery.
Limitations
The study relies on database analyses which may not capture all clinical variables and lacks information on chemotherapy administered.
Participant Demographics
The study included 31,573 patients with pancreas cancer, with a median age of 68 years, and a majority were White.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% c.i. 1.15–1.25 for group 2; 95% c.i. 1.45–1.80 for group 4
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website